KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Total Current Liabilities (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Total Current Liabilities data on record, last reported at $277.1 million in Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 29.82% year-over-year to $277.1 million; the TTM value through Dec 2025 reached $277.1 million, down 29.82%, while the annual FY2025 figure was $277.1 million, 29.82% down from the prior year.
  • Total Current Liabilities reached $277.1 million in Q4 2025 per ACAD's latest filing, down from $356.6 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $394.9 million in Q4 2024 and bottomed at $88.2 million in Q3 2021.
  • Average Total Current Liabilities over 5 years is $220.9 million, with a median of $217.0 million recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: surged 102.38% in 2023, then decreased 29.82% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $96.1 million in 2021, then surged by 30.77% to $125.6 million in 2022, then soared by 102.38% to $254.3 million in 2023, then surged by 55.31% to $394.9 million in 2024, then fell by 29.82% to $277.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $277.1 million in Q4 2025, $356.6 million in Q3 2025, and $330.0 million in Q2 2025.